Stevanato Group (STVN) Stock Price, News & Analysis

Company Overview

Stevanato Group S.p.A. is an Italy-based developer and manufacturer of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. The company provides products and services designed to support the development, production and administration of injectable medicines.

Its portfolio includes glass vials, cartridges and syringes, as well as other primary packaging components and containment systems. Stevanato Group also offers inspection and packaging equipment, analytical and laboratory services, and drug-delivery technologies such as prefillable syringes and combination-device solutions. These offerings are used across a range of pharmaceutical manufacturing and clinical-development applications.

Founded in 1949 by Giovanni Stevanato, the company has expanded from its Italian origins into an international organization serving customers in pharmaceutical and biotechnology markets worldwide. Stevanato Group is headquartered in Piombino Dese, Italy, and operates manufacturing, research and service facilities across Europe, North America and Asia. Its shares trade on the New York Stock Exchange under the symbol STVN.

Key Stats

• Today's Range: €20.91 to €21.79
• 50-Day Range: €19.11 to €22.70
• 52-Week Range: €12.89 to €28.00
• Volume: 205,700 shs
• Average Volume: 518,281 shs
• Market Capitalization: €6.55 billion
• P/E Ratio: 38.61
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Stevanato Group Stock Analysis - MarketRank™

Stevanato Group scored higher than 42% of companies evaluated by MarketBeat, and ranked 606th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Stevanato Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 2 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Stevanato Group has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 17.39%

Earnings Growth

Earnings for Stevanato Group are expected to grow by 17.39% in the coming year, from €0.69 to €0.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stevanato Group is 38.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stevanato Group is 38.61, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.01.

Price to Earnings Growth Ratio

Stevanato Group has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Stevanato Group has a P/B Ratio of 3.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.37% of the float of Stevanato Group has been sold short.

Short Interest Ratio / Days to Cover

Stevanato Group has a short interest ratio ("days to cover") of 2.39, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Stevanato Group has recently increased by 9.49%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: N/A

Dividend Yield

Stevanato Group does not currently pay a dividend.

Dividend Growth

Stevanato Group has only been increasing its dividend for 1 years.

Dividend Sustainability

Based on earnings estimates, Stevanato Group will have a dividend payout ratio of 7.41% next year. This indicates that Stevanato Group will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Stevanato Group this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Stevanato Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought €0.00 in company stock and sold €166,285.00 in company stock.

Percentage Held by Insiders

0.70% of the stock of Stevanato Group is held by insiders.

Percentage Held by Institutions

Stevanato Group has minimal institutional ownership at this time.

Company Calendar

• Record date for 7/29 Dividend: 6/11/2026
• Ex-Dividend for 7/29 Dividend: 6/11/2026
• Dividend Payable: 7/29/2026
• Last Earnings: 8/05/2026
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:STVN
• CIK: 1849853
• Web: www.stevanatogroup.com
• Phone: 39049931811
• Fax: N/A
• Employees: 6,010
• Year Founded: 1949

Profitability

• EPS (Trailing Twelve Months): €0.56
• Trailing P/E Ratio: 38.61
• Forward P/E Ratio: 31.33
• P/E Growth: 1.77
• Net Income: €158.21 million
• Net Margins: 10.99%
• Pretax Margin: 15.59%
• Return on Equity: 10.43%
• Return on Assets: 6.16%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 1.61
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: €1.34 billion
• Price / Sales: 4.88
• Cash Flow: €0.88 per share
• Price / Cash Flow: 24.60
• Book Value: €5.55 per share
• Price / Book: 3.90

Miscellaneous

• Outstanding Shares: 302,840,000
• Free Float: 300,723,000
• Market Cap: €6.55 billion
• Optionable: Optionable
• Beta: 0.75